Pre-made Tibulizumab biosimilar ( Bispecific Mixed mAb and scFv, anti-TNFSF13B;IL17A therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-568
Anti-TNFSF13B;IL17A therapeutic antibody (Pre-made Tibulizumab biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tibulizumab is a subcutaneously administered, bispecific antibody that targets B-?cell activating factor (BAFF) and interleukin-17, being developed by Eli Lilly.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-TNFSF13B;IL17A therapeutic antibody (Pre-made Tibulizumab biosimilar,Bispecific Mixed mAb and scFv)|
|Format||Bispecific Mixed mAb and scFv|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;6nou:AA/6nov:AB|
|Conditions Discontinued||Rheumatoid arthritis;Sjogren's syndrome|